Reference · cited facts
Tirzepatide
Mounjaro / ZepboundHalf-life ≈5 daysFDA-approvedReviewed July 2026
Educational information and a math tool only — not medical advice, a dose recommendation, or an endorsement of peptide use. Consult a licensed healthcare provider before starting, stopping, or changing anything.
Class / mechanism
Tirzepatide is an FDA-approved GIP/GLP-1 receptor agonist marketed as Mounjaro and Zepbound.
SOURCE [1]
Regulatory status
FDA-approved as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management). Prescription only.
FDA · July 2026
Reported half-life
≈5 days
PUBMED
Human evidence
Established (FDA-approved)
LITERATURE
What the literature reports
- Tirzepatide is an FDA-approved GIP/GLP-1 receptor agonist marketed as Mounjaro and Zepbound.
- Its published elimination half-life is approximately 5 days, supporting once-weekly administration.
- Approved products are supplied ready-to-use (pens/vials); a licensed prescriber sets the dose.
Honest caveats
- • This is a prescription medicine — obtain and dose it only through a licensed clinician.
- • Compounded or “research” versions are not the FDA-approved product.
Reconstitution calculator
Enter your own vial size, BAC water and target dose — get exact syringe units.
Sources